Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 2004

View Archived Issues

Opioid growth factor phase I trial in patients with advanced inoperable pancreatic carcinoma

Talaporfin reported to reduce choroidal leakage in ARMD

Biocryst reports exciting progress during past quarter

Avant Immunotherapeutics achieves notable milestones in the first quarter

Novel human anticancer vaccine elicits cellular responses

Insight into mechanism of action of AGI-1067

Laquinimod reported to delay progression of multiple sclerosis

Clinical benefits of pramlintide in the treatment of diabetes

Rasagiline improves motor fluctuations and freezing of gait in advanced PD

Promising results reported for AdPEDF.11 in choroidal neovascularization

Prous Science's LifeSci Channel posts several new exiting programs

Five series of ALK5 kinase inhibitors presented by Pfizer

AstraZeneca claims 11beta-HSD1 inhibitors for diabetes, obesity, etc.

Cyclic peptide with glucagon antagonist activity isolated from Streptomyces cultures

New cannabinoid CB1 antagonists/inverse agonists claimed by Pfizer

Pfizer patent covers p38 MAP kinase inhibitors and their therapeutic use

French researchers describe imidazoline-based glucose and lipid lowering agents

First portion of Entereg NDA submitted

Biovitrum and Symphogen enter recombinant polyclonal antibody collaboration

Visudyne launched in Japan

ARIC data support stroke predictive value of Lp-PLA2

CTA submitted for Canadian phase I trials of TAFA-93

New phase II trial for Aplidin in SCLC

Sysmex collaboration to test automated cervical cancer screening technology

Exanta completes E.U. mutual recognition procedure

SPA for phase III GVAX prostate cancer vaccine trial

IDEA-070 reduces cutaneous inflammation

HE-2000 reduces HIV load, opportunistic infections in AIDS patients

Tolevamer development advances based on study results

Recent results with tamsulosin reported at AUA annual meeting

Study shows melatonin improves nocturia

Peptimmune licenses rights to GT389-255 from Genzyme

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...